Editor’s Pick: Seaport Therapeutics | Nature Biotechnology

Each year, Nature Biotechnology highlights companies that received sizeable early-stage funding in the previous year. Seaport Therapeutics is modifying central nervous system drugs for delivery through the lymphatic system, bypassing first-pass liver metabolism.